RT info:eu-repo/semantics/doctoralThesis
T1 Seguridad de bevacizumab en pacientes con cáncer con enfermedad inflamatoria intestinal: experiencia preliminar unicentro
A1 Herrera Gómez, Ruth Gabriela
A2 Universidad de Valladolid. Escuela de Doctorado
K1 Oncologia
K1 Safety
K1 Cancer
K1 Oncology research
K1 Investigación oncológica
K1 Seguridad
K1 3201.01 Oncología
AB There are limited information is available on the safety of treatment with bevacizumab in combination with chemotherapy in patients with inflammatory bowel disease (IBD) and tumors of the gastrointestinal tract and extra-intestinal. This doctoral thesis manuscript presents a cross-sectional evaluation of data collected retrospectively from adult patients with cancer and IBD treated at a referral center for cancer treatment (study period: between April 1, 2007 and May 31, 2016). . The information of these patients was collected from electronic health records, and all records from which it was accessed, following current recommendations for conducting and presenting studies with real-world data. In total, twenty-seven patients with IBD (Crohn's disease, n = 22; colitis, n = 5) were treated with bevacizumab and chemotherapy after developing cancer. At the time of diagnosis of malignancy, 18 patients had IBD in remission and 9 had IBD with activity classified as moderate. Among those with moderately active IBD, 5 had received corticosteroids, and one patient with IBD in remission had received infliximab, all within 6 months of cancer diagnosis. The cancers treated were colorectal cancer (n = 13), small intestine cancer (n = 4), non-small cell lung cancer (n = 3), breast cancer (n = 3), and other cancers (n = 4). Patients received bevacizumab in combination with chemotherapy as first-line (n = 18) or second-line (n = 9) treatment, for an average period of 6.7 months. The following adverse drug effects were recorded, all of which were grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: proteinuria (n = 2) , hypertension (n = 1), orogingival fistula (n = 1), epistaxis (n = 1), diarrhea (n = 1), rectal bleeding (n = 1), intestinal perforation (n = 1), neutropenia (n = 2), and thrombopenia (n = 1). Progression-free survival (PFS) was more than 5 months. No IBD flares were observed during bevacizumab treatment. It can be concluded that bevacizumab combined with chemotherapy is safe in this group of patients and is not associated with less efficacy in IBD patients who develop cancer.
YR 2024
FD 2024
LK https://uvadoc.uva.es/handle/10324/69481
UL https://uvadoc.uva.es/handle/10324/69481
LA spa
NO Escuela de Doctorado
DS UVaDOC
RD 28-nov-2024